OR WAIT null SECS
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Despite a growing number of biosimilar approvals, market uptake remains a challenge.
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
March 19, 2024
Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel) marks the first gene therapy approved in the US for treating children with metachromatic leukodystrophy.
March 15, 2024
ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection
March 13, 2024
Under a new agreement, Chime Biologics will manufacture Domain Therapeutics’ antibody cancer immunotherapy candidate, DT-7012.
March 12, 2024
The Italian company’s North American business has seen an increase of 47%.
March 11, 2024
The Alliance will receive the NSF Regional Innovation Engines Development Award and $1 million in funding.
March 02, 2024
The authors evaluated the potential of direct filtration for multiple biopharmaceutical candidates. This article is Part 2 of the study.
Proprietary cell lines offer opportunities for achieving high AAV titers.
A tidal wave of questions floats the need for more upstream automation.